Figure 1.
Characterization and validation of the D/THL cell lines. (A) EBNA (Epstein–Barr virus nuclear antigen 1) polymerase chain reaction assay of COH cell lines with negative control, an EBV-positive (Raji) and EBV-negative (Jurkat) cell line. QC235 is a positive control separately performed to confirm that DNA samples are amplifiable. (B) Growth plot for COH-DHL1 and COH-THL1 cell lines within 8 days with y-axis log2 transformed and doubling time (Td) labeled. (C) Representative figure of mice with tumor highlighted in the box after subcutaneous injection of COH-DHL1 (left) and COH-THL1 (right). (D) Flow cytometry results of the 2 cell lines with their mice tumors. (E) Sigmoidal dose–response curves showing responses of 6 cell lines to 10 different drugs.

Characterization and validation of the D/THL cell lines. (A) EBNA (Epstein–Barr virus nuclear antigen 1) polymerase chain reaction assay of COH cell lines with negative control, an EBV-positive (Raji) and EBV-negative (Jurkat) cell line. QC235 is a positive control separately performed to confirm that DNA samples are amplifiable. (B) Growth plot for COH-DHL1 and COH-THL1 cell lines within 8 days with y-axis log2 transformed and doubling time (Td) labeled. (C) Representative figure of mice with tumor highlighted in the box after subcutaneous injection of COH-DHL1 (left) and COH-THL1 (right). (D) Flow cytometry results of the 2 cell lines with their mice tumors. (E) Sigmoidal dose–response curves showing responses of 6 cell lines to 10 different drugs.

Close Modal

or Create an Account

Close Modal
Close Modal